Find News

Filter articles

Showing 3091 to 3100 of 3438 results

Sanofi and MannKind strike Afrezza deal


French pharmaceutical company Sanofi and the US-based MannKind Corporation have entered into an exclusive licensing agreement to develop and commercialise MannKind’s Afrezza (insulin human), an inhalable insulin therapy for adults with types 1 and 2 diabetes.

Merck sues to block Cancidas generic

US11-08-2014Legal developments

New Jersey-based pharmaceutical company Merck has sued generic drug maker Fresenius for infringing patents relating to its anti-fungal injection Cancidas (caspofungin acetate).

FDA issues guidance on biologics’ exclusivity period


The US Food and Drug Administration (FDA) has issued guidance for biological drug makers about what information they should provide the agency to determine when their products’ marketing exclusivity period should begin, known as the “date of first licensure”.

Federal Circuit judges split on temazepam ‘sham’ case

US07-08-2014Legal developments

The US Court of Appeals for the Federal Circuit has affirmed a district court’s decision that pharmaceutical company Tyco’s patents directed to sleep aid drug temazepam were not infringed.

US District Court judge throws out Takeda’s case against Mylan

US06-08-2014Legal developments

US District Court for the Northern District of California judge Lucy Koh has dismissed Japanese pharmaceutical company Takeda’s patent infringement case against generic maker Mylan concerning acid reflux drug Dexilant (dexlansoprazole).

Akorn settles with FTC to allow VersaPharm merger

US05-08-2014Mergers & acquisitions

US-based injections maker Akorn has agreed to sell its rights to develop, manufacture and market generic tuberculosis injection rifampin to Watson Laboratories to settle charges by the US Federal Trade Commission (FTC) that its proposed acquisition of pharmaceutical company VersaPharm was likely to be anticompetitive.

RNA-targeting drugs behind Roche’s acquisition of Santaris

Switzerland05-08-2014Mergers & acquisitions

New drugs that target ribonucleic acid (RNA) being developed by Danish biotechnology company Santaris Pharma lie behind the decision by Roche to buy Santaris that was announced yesterday, August 4.

AstraZeneca sues Zydus to protect Nexium

US04-08-2014Legal developments

Anglo-Swedish pharmaceutical company AstraZeneca has sued India-based Zydus for infringing three patents related to its heartburn drug Nexium (esomeprazole magnesium).

Boehringer sues Mylan over aspirin product


German pharmaceutical company Boehringer Ingelheim has sued generic drug maker Mylan for infringing a patent covering its Aggrenox drug.

Pfizer acquires Baxter vaccines for $635m

US31-07-2014Mergers & acquisitions

Pfizer has entered into a definitive agreement to acquire two vaccines marketed by US biotechnology company Baxter International for $635 million.

Showing 3091 to 3100 of 3438 results